Phase II

Webinar

Conversation Between a Sponsor and a Statistician About Phase II/III Trials in Oncology

June 23, 2022
Article

Considerations on the Mechanics and Sample Sizes for Early Trials of Targeted Agents and Immunotherapy in Oncology

June 28, 2021

When every data point represents a patient, accuracy and integrity aren’t optional — they’re everything. That’s why it’s IDDI.

Start Now